Anorexia Nervosa – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Anorexia nervosa is a severe eating disorder characterized by significant weight loss and is considered a serious mental health condition with potentially life-threatening consequences. It is the primary cause of weight loss among young women and a leading reason for admission to child and adolescent hospital services. The precise origins of eating disorders remain a subject of incomplete comprehension, yet there is a prevailing belief that a confluence of biological, psychological, and social elements play a role in the emergence of these conditions. The primary medical complications in anorexia nervosa arise from an imbalance between energy intake and requirements, resulting in a state of reduced metabolism. The body attempts to maintain stability in the malnourished state by downregulating various functions, leading to the observed signs and symptoms of anorexia nervosa. Depression and anxiety disorders are two commonly observed psychiatric comorbidities in individuals with anorexia nervosa. The recovery process from anorexia nervosa typically spans an average of five to six years from the time of diagnosis, and up to 30% of patients may not achieve full recovery. Key symptoms of anorexia nervosa include extremely restricted eating, severe thinness (emaciation), an intense pursuit of thinness and resistance to maintaining a normal or healthy weight, a profound fear of weight gain, distorted body image, and self-esteem heavily influenced by perceptions of body weight and shape or a lack of recognition of the seriousness of low body weight. Anorexia nervosa is categorized into two subtypes: the "restrictive" subtype, where individuals severely limit the amount and type of food they consume, and the "binge-purge" subtype, where individuals also restrict their food intake but may also experience episodes of binge-eating followed by purging behaviors such as self-induced vomiting, laxative use, or diuretic abuse.
·
Approximately 9% of the United States
population (28.8 million Americans) is affected by eating disorders.
Thelansis’s “Anorexia Nervosa Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Anorexia Nervosa treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Anorexia Nervosa across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Anorexia Nervosa Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment